Navigation Links
Clue to switch of bladder cancer from locally contained to invasive found by Jefferson scientists
Date:5/14/2010

(PHILADELPHIA) Bladder cancer often becomes aggressive and spreads in patients despite treatment, but now researchers at the Kimmel Cancer Center at Jefferson have identified a protein they believe is involved in pushing tumors to become invasive and deadly.

"We have found that IGF-IR is a critical regulator of motility and invasion of bladder cancer cells, and this could offer us a novel molecular target to treat patients with this cancer in order to prevent metastasis," said the lead investigator, Andrea Morrione, Ph.D., a research associate professor of Urology at Jefferson Medical College, and director of Urology Research, Kimmel Cancer Center.

This finding is promising, they say in the June issue of American Journal of Pathology, because there are about a dozen agents targeted against the protein, the insulin-like growth factor receptor I (IGF-IR), that are now undergoing clinical testing to treat a variety of patient tumors.

"Testing presence of the protein could also serve as a novel tumor biomarker for diagnosis, and possibly prognosis of bladder tumors," he added.

Although bladder cancer is common, the molecular mechanisms that push the cancer to become invasive and to spread are still poorly understood, say the researchers. Although most bladder cancers are caught early and treated, they often come back and become aggressive, despite subsequent therapy with surgery, chemotherapy, or immunotherapy.

In this study, the researchers looked at the role of the protein receptor for the growth factor IGF-I, an important modulator of cell proliferation in bladder cancer cells. They found that although activation of IGF-IR did not affect growth of bladder cancer cells, it did promote the migration and invasion of these cells. The researchers showed that IGF-IR activated other molecules in cancer-promoting pathways (Akt and MAPK) that allow cancer cells to break its bond with other cells in a tumor in order to travel to others sites in the body.

"These data seem to indicate that this protein receptor may play a more prominent role in later stages of bladder cancer, not in the initiation of the cancer," said Dr. Morrione.

Additional work is needed to validate the role of IGF-IR in pushing bladder cancer into an invasive form, but if the results continue to be promising, it might be possible to test anti IGF-IR therapies in bladder cancer and to see how effective a test for these proteins in bladder tumor biopsies might predict cancer spread, the researchers say.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Brains master switch is verified by Iowa State University researcher
2. UBC graduate student finds a start/stop switch for retroviruses
3. Discovery of cellular switch may provide new means of triggering cell death, treating disease
4. Researchers discover brain tumors grow-or-go switch
5. Daylight-Saving Time Switch May Leave You Sleepy, U-M Physician Says
6. BCS Global Launches PSVN (Public Switched Video Network), an Initiative to Provide a Framework for Inter-Connecting Business to Business Video Networks
7. Researchers create drug to keep tumor growth switched off
8. Cochlear Appoints Switched on Media to Develop its SEO Across the Asia Pacific Region
9. Scientists show how molecular switch helps pancreatic cancer beat drugs
10. Boston Celtics Captain Paul Pierce Partners with Switch2Health to Inspire Youth to Lead Healthier Lifestyles through Innovative Rewards-based Fitness System
11. Lack of cellular enzyme triggers switch in glucose processing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... symplrTM, a leading provider ... announced that Kyle Allain has joined the company as Vice President and General ... including provider, payor and managed care solutions. , A seasoned executive with ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... are expected to be diagnosed globally; approximately 25,000 of them will be malignant.(1) ... greater use of this type of healthcare model in the diagnosis and treatment ...
(Date:4/24/2017)... ... April 24, 2017 , ... Rod Burkett, CEO of Gardant Management Solutions, was ... has been at the forefront of Gardant since it was founded in 1999. His ... the opening of more than 40 new senior living communities. With his leadership, Gardant ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... As ... is worth a thousand words. The good news for single women is that she ... Attraction," which is available on April 25th. Joan's insight, personal experiences and sparkling sense ...
(Date:4/24/2017)... ... April 24, 2017 , ... Labs often perform the same ... lab operators and management to assess these processes with a critical eye—particularly in ... actions. , Created with the help of both internal and external process ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has announced ... Driven by Rapidly Expanding Injectables Market and Increasing Usage of Complex ... ... technologies will rise from USD 20 Billion in 2015 to around ... Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market and ...
(Date:4/20/2017)... -- Research and Markets has announced the addition ... Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ... ... valued at US$ 7,167.6 Mn in 2015, and is expected ... CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
Breaking Medicine Technology: